The General Meeting decided on 19 January 2011 to give a Subsequent Offering to Eligible Shareholders following the completed private placement from 22 December 2010.

Biotec Pharmacon has now received approval from the Financial Supervisory Authority of Norway (Finanstilsynet) on the following prospectus:

The Subsequent Offering of up to 1,200,000 Offer Shares at an Offer Price of NOK 6.30 per Offer Share with non-transferable preferential rights for Eligible Shareholders as of 22 December 2010.

Subscription Period for the Subsequent Offering: 28 January - 10 February 2011 at 17:30 (CET), both dates inclusive. Preferential rights not used to subscribe for Offer Shares before the expiry of the Subscription Period will be of no value and will lapse without compensation to the holder.

Eligible Shareholders as of 22 December 2010, as registered in the VPS on 28 December 2010, have non-transferable preferential rights to participate in the subsequent offering. Eligible shareholders will be notified in a separate letter with an overview of rights allocated. Oversubscription is allowed.

For further details, please enter the prospectus dated 27 January 2011.

Download the application form here.

Norwegian citizens may use a link to VPS for internet application: VPS link

Eligible shareholders outside Norway not registrated in Norwegian VPS, must make their applications through their local manager or bank.

The prospectus and application form for the subsequent offering is  also available at the website of the manager SEB Enskilda (www.sebenskilda.no).
 
The prospectus can also be received free of charge on request to the manager or the company.